Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)

This study has been completed.
Sponsor:
Information provided by:
National Multiple Sclerosis Society
ClinicalTrials.gov Identifier:
NCT00695084
First received: June 9, 2008
Last updated: June 10, 2008
Last verified: June 2008
  Purpose

This trial will evaluate whether progressive multiple sclerosis associated with hemiparesis may benefit from Constraint-Induced Movement Therapy.


Condition Intervention Phase
Multiple Sclerosis
Behavioral: Constraint-Induced Movement Therapy
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Constraint-Induced Movement Therapy Trial for Progressive Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by National Multiple Sclerosis Society:

Primary Outcome Measures:
  • Improvement on the Motor Activity Log [ Time Frame: One year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Improvement on the Wolf Motor Function Test [ Time Frame: Pre to post-treatment ] [ Designated as safety issue: No ]

Enrollment: 7
Study Start Date: March 2007
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Treatment with Constraint-Induced Movement Therapy
Behavioral: Constraint-Induced Movement Therapy
Intensive practice with the hemiparetic arm for 30 contact hours
Other Name: CI Therapy

Detailed Description:

Constraint-Induced Movement Therapy was developed to treat stroke hemiparesis. Due to the similarity between multiple sclerosis and stroke in terms of chronic motor deficit, this trial will attempt to determine whether multiple sclerosis may benefit similarly from Constraint-Induced Movement Therapy.

  Eligibility

Ages Eligible for Study:   21 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic upper extremity motor deficit due to multiple sclerosis

Exclusion Criteria:

  • Relapse within 3 months of planned enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00695084

Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35249
Sponsors and Collaborators
National Multiple Sclerosis Society
Investigators
Principal Investigator: Victor W Mark, MD University of Alabama at Birmingham
  More Information

No publications provided

Responsible Party: Patricia O'Looney, National Multiple Sclerosis Society
ClinicalTrials.gov Identifier: NCT00695084     History of Changes
Other Study ID Numbers: CIMSTrial, PP1395
Study First Received: June 9, 2008
Last Updated: June 10, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by National Multiple Sclerosis Society:
multiple sclerosis

Additional relevant MeSH terms:
Multiple Sclerosis
Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on August 28, 2014